Moderna's new flu vaccine, based on the same mRNA technology used in its COVID-19 shot, showed promising results in a major ...

The capped upside and unlimited downside risk make MRNY unattractive unless Moderna's share price stabilizes and recovers ...

Moderna stock is indeed in the doldrums today, but this offers the opportunity to buy at a reasonable price, and, 10 years ...

The company was pleased to report the findings of a late-stage clinical trial of its advanced flu vaccine. Moderna (NASDAQ: ...

Moderna said on Monday its influenza vaccine was found to be 26.6% more effective than an approved annual flu shot from GSK ...

The biotechnology company’s messenger RNA flu vaccine candidate showed positive results in a late-stage trial.

Moderna Inc. said Monday its experimental flu shot showed positive results in a late-stage trial.   In a Phase 3 study, the ...

The phase three study data clears the path forward for Moderna’s combination jab targeting Covid-19 and influenza.

Moderna this week announced positive data from a phase 3 trial of its messenger RNA vaccine against seasonal influenza, which ...

The Cambridge biotech believes packaging the two immunizations together will lead to higher uptake of COVID vaccines.

The U.S. Centers for Disease Control and Prevention has ended its emergency response to the H5N1 bird flu outbreak, a move ...

Moderna stock is indeed in the doldrums today, but this offers the opportunity to buy at a reasonable price, and, 10 years down the road, potentially benefit from a huge biotech growth story.